Preface on STARD Guideline1
STARD guidelines: another piece of an intricate puzzle for evaluating the quality of scientific publishing
Annals of Translational Medicine
2016;
4
(3)
:42
(February 2016)
Editorial on STARD Guideline1
Improving accuracy of diagnostic studies in a world with limited resources: a road ahead
Annals of Translational Medicine
2016;
4
(3)
:43
(February 2016)
The standards for reporting diagnostic accuracy studies 2015 update: is there a missing link to the triumvirate?
Annals of Translational Medicine
2016;
4
(3)
:44
(February 2016)
A STAR-Document for those interested in evaluating diagnostic research studies
Annals of Translational Medicine
2016;
4
(3)
:45
(February 2016)
STARD guideline in diagnostic accuracy tests: perspective from a systematic reviewer
Annals of Translational Medicine
2016;
4
(3)
:46
(February 2016)
Editorial on Newer Agents to Enhance Radiotherapeutic Outcomes2
Enhancing radiotherapy: breaking free from undue zeal for the existent, and utter contempt for the prospective
Annals of Translational Medicine
2016;
4
(3)
:47
(February 2016)
Original Article on Newer Agents to Enhance Radiotherapeutic Outcomes2
Prospective randomized study comparing concomitant chemoradiotherapy using weekly cisplatin & paclitaxel versus weekly cisplatin in locally advanced carcinoma cervix
Annals of Translational Medicine
2016;
4
(3)
:48
(February 2016)
Review Article on Newer Agents to Enhance Radiotherapeutic Outcomes2
Novel agents and treatment techniques to enhance radiotherapeutic outcomes in carcinoma of the uterine cervix
Annals of Translational Medicine
2016;
4
(3)
:49
(February 2016)
Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma
Annals of Translational Medicine
2016;
4
(3)
:50
(February 2016)
Immunological interactions in radiotherapy—opening a new window of opportunity
Annals of Translational Medicine
2016;
4
(3)
:51
(February 2016)
Chemically enhanced radiotherapy: visions for the future
Annals of Translational Medicine
2016;
4
(3)
:52
(February 2016)
Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview
Annals of Translational Medicine
2016;
4
(3)
:53
(February 2016)
Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma
Annals of Translational Medicine
2016;
4
(3)
:54
(February 2016)
Perspective on Newer Agents to Enhance Radiotherapeutic Outcomes2
Radiotherapy to volumes defined by metabolic imaging in gliomas: time to abandon monstrous margins?
Annals of Translational Medicine
2016;
4
(3)
:55
(February 2016)
Big-data Clinical Trial Column3
Multiple imputation for time series data with Amelia package
Annals of Translational Medicine
2016;
4
(3)
:56
(February 2016)
Case Report
A case of immunoglobulin G4-related constrictive pericarditis
Annals of Translational Medicine
2016;
4
(3)
:57
(February 2016)
18F-FDG PET/CT in multicentric Castleman disease: a case report
Annals of Translational Medicine
2016;
4
(3)
:58
(February 2016)
Commentary
The impact of preanalytical variability in clinical trials: are we underestimating the issue?
Annals of Translational Medicine
2016;
4
(3)
:59
(February 2016)
STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy
Annals of Translational Medicine
2016;
4
(3)
:60
(February 2016)
Treatment options and outcomes for lower pole stone management: are we there yet?
Annals of Translational Medicine
2016;
4
(3)
:61
(February 2016)
Venous-to-arterial carbon dioxide differences and the microcirculation in sepsis
Annals of Translational Medicine
2016;
4
(3)
:62
(February 2016)
Letter to the Editor
Intra-articular platelet-rich plasma for the treatment of osteoarthritis
Annals of Translational Medicine
2016;
4
(3)
:63
(February 2016)
Disclosure:
1. The series “STARD Guideline” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. Giuseppe Lippi served as the unpaid Guest Editor for the series.
2. The series “Newer Agents to Enhance Radiotherapeutic Outcomes” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. Swaroop Revannasiddaiah served as the unpaid Guest Editor for the series.
3. The series “Big-data Clinical Trial Column” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding.
